The Indian stock market has faced significant headwinds this year, with the Nifty 50 down nearly 10% year-to-date due to elevated crude oil prices from Middle East conflict, heavy foreign capital outflow, rupee weakness against the US dollar, and lack of AI trade. According to reports from Master Capital Services, the prevailing situation requires prudence in stock selection, prompting Chief Research Officer Ravi Singh to recommend 10 stocks for long-term investment. These recommendations span across sectors including real estate, IT, defence, chemicals, healthcare, power, pharmaceuticals, mining, and commodity exchanges.
DLF emerges as the top pick with a 12-month target price of ₹800 and 41% upside potential from its previous close of ₹566.75. As reported by Master Capital Services, Singh highlighted that DLF is completely owning the luxury housing market with their ''Privana'' series essentially sold out overnight. The company has drastically cut down net debt while continuing to push pre-sales higher, with a heavy pipeline lined up for Gurugram and Goa. Bharat Electronics (BEL) follows with a 12-month target of ₹515 and 22% upside potential from ₹423.65, benefiting from defence sector booming and sitting on an all-time high order book. According to Univest's latest analyst review, BEL is trading at ₹310 with technical support in the ₹214-₹294 band and resistance near ₹329-₹335, while the consensus target remains at ₹360 with a bull case of ₹420 and bear case of ₹200.
Coforge presents a mid-cap IT opportunity with a 12-month target of ₹1,565 and 22% upside potential from ₹1,282.10, despite sector risks. According to Singh's analysis, Coforge remains a massive outlier with excellent execution and a massive executable order book, particularly strong in banking, financial services, and travel sectors. Aurobindo Pharma offers 16% upside potential with a target of ₹1,755 from ₹1,511.80, as the company successfully pivots from generic drugs to complex speciality pharma with recent biosimilar approvals and PLI scheme operationalisation. Astrazeneca Pharma India is among the stocks to buy today for its position within India's leading pharma sector, with the Nifty Pharma index hitting a 52-week high in May 2026. The company operates in oncology, cardio-metabolism and respiratory therapy areas, partnering with Dr. Reddy's and Sun Pharma for distribution of key molecules including Ticagrelor, Saxagliptin and Dapagliflozin.
NTPC is positioned as India's green energy powerhouse with a 12-month target of ₹466 and 18% upside potential from ₹395.25, targeting aggressive 60GW renewable capacity by 2032. Singh highlighted the company's better plant load factors and falling coal under-recoveries, while Coal India offers 16% upside potential with a target of ₹535 from ₹462.20, benefiting from strong production records and efficient cost control. Hindustan Zinc is the standout addition to today's watchlist, with the Government of India announcing fresh silver import restrictions and a 15% import duty hike from May 13, 2026. Hindustan Zinc is India's largest silver producer and the world's third-largest integrated zinc producer, with every domestic silver price increase translating directly into higher revenue and margin at zero additional production cost.
SRF presents a chemical sector recovery story with 21% upside potential to ₹3,245 from ₹2,689.50, benefiting from a V-shaped recovery in fluorochemicals and massive capex investment in speciality chemicals. Multi Commodity Exchange of India (MCX) rounds out the recommendations with a 7% upside potential to ₹3,625 from ₹3,391, as options trading explosion drives operating leverage and profitability spike from reduced legacy software costs. Suzlon Energy features as India's largest renewable energy solutions provider, with Q3 FY26 net profit growth of 15.08% year-on-year to ₹445.28 crore and FY26 full-year revenue reaching ₹10,993 crore with PAT of ₹2,072 crore. The S144 flagship turbine has secured over 5 GW in firm orders and accounts for 91% of Suzlon's 5.6 GW order book.
